MDS (Myelodysplastic Syndrome)WATCH TranfuseNCT07511829
WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment
An observational study of MDS (Myelodysplastic Syndrome) and AML (Acute Myeloid Leukemia), run by University of Oxford at 1 site in United Kingdom.
Trial summary
Cancer treatments such as chemotherapy often affect healthy cells as well as the cancer cells and this can lead to side-effects such as low blood counts - anaemia. This can cause severe fatigue, shortness of breath and brain fog and may need regular blood transfusions. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)
- What is being tested?
- Axvitiy Ax3 accelorometer
- Type of treatment
- Medical device
- How many people
- 80 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 17 Feb 2026to 1 Sep 2027
- How long will I take part?
- 2 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants will be patients who have been diagnosed with haematological malignancies (MDS, AML and myeloma)
Who may be able to join
- Patients aged ≥18 years with WHO-defined MDS or mixed myeloproliferative/myelodysplastic neoplasm overlap syndromes (MPN/MDS), myeloma and AML
- Intention to undertake disease modifying treatment
- Life expectancy ≥ 6 months
- Able to complete quality of life questionnaires
- Willing and able to provide informed consent for participation in the study
- Willing to receive blood products as part of normal NHS care
Who cannot join
- Poor performance/functional status (Eastern Cooperative Oncology Group system ECOG ≥3)
- Participants with known arrhythmias or other significant cardiological conductivity disorders
- Patients with severe comorbidities
- Patients with known skin allergies or conditions that in the opinion of the investigator would compromise the safety of the patient or quality of the data
- Hospitalised patients
- Patients currently participating in another interventional clinical study
- Patients with a pacemaker or implanted cardioverter defibrillator or any cardiac implanted device
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Oxford University Hospitals NHS Trust
Oxford, OXFORDSHIRE, OX39DU
matthew H Poynton, MBBS, +447742990230, matthew.poynton@linacre.ox.ac.uk
matthew.poynton09@gmail.com
About this study
Cancer treatments such as chemotherapy often affect healthy cells as well as the cancer cells and this can lead to side-effects such as low blood counts - anaemia. This can cause severe fatigue, shortness of breath and brain fog and may need regular blood transfusions. Their quality of life (QoL) is often very poor during treatment because of these side effects, and it is hard to deal with.
Doctors use blood tests to decide whether a patient is well enough for treatment and when to start treatment. However, blood tests do not tell us how a person feels, and it is not the same in everyone. We need a better way for doctors to monitor patients' QoL and these symptoms so that they are physically and emotionally able to continue their treatment. It is hard for doctors to accurately assess this through speaking to their patients and doctors do not record or discuss these effects of treatment very well with patients.
Read more
The aim of this study is to better understand how people feel during their treatment and how we can best use blood transfusions to maintain QoL.
80 adult patients who are starting blood cancer treatments will be asked to answer questionnaires about how they are feeling and their symptoms during their treatment. Participants will be asked to wear a smartwatch to measure their physical activity levels. Activity data collected will then be compared with their reported QoL and blood counts to help us understand when patients can tolerate difficult treatments the best and how blood transfusions affect this.
Patients, their family and carers will be invited to take part in an interview to understand their views on how we can improve their care, QoL and access to transfusions.
A better understanding of the impact of low blood counts on QoL can help us use blood transfusions to benefit patients' lives. This work will better match transfusions to individual peoples' needs and therefore 'personalise' blood transfusion care.
- Being tested
- Axvitiy Ax3 accelorometer
- Medical subject headings
- Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Axvitiy Ax3 accelorometerDevice
Participants will wear the accelometer for 2 months
| Study group | Role | What they receive |
|---|---|---|
| MDS | Participants with MDS Receives: Device: Axvitiy Ax3 accelorometer | |
| AML | Participants with AML Receives: Device: Axvitiy Ax3 accelorometer | |
| Myeloma | Participants with myeloma Receives: Device: Axvitiy Ax3 accelorometer |
What is being measured
The primary outcome is the main question the study is designed to answer.
Activity Monitoring
To collect QoL data and activity data during an observational study to understand QoL through 2 treatment cycles of treatment exploring correlations of QoL with both Haemoglobin (Hb) and activity data.
Measured: 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Apr 2026
- Study start17 Feb 2026
- Primary completion1 Apr 2027 (estimated)
- Study completion1 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MDS (Myelodysplastic Syndrome)Studies of the same condition, open and under way.
- More trials run by University of OxfordThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
- Target duration
- 2 Months
Sponsor and investigators
- Lead sponsor
- University of Oxford
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Matthew H Poynton, MBBS, Principal investigator, University of Oxford
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07511829
- Sponsor's protocol ID
- 18950
- Acronym
- WATCH Tranfuse
- Status last verified
- Feb 2026
- First submitted
- 30 Mar 2026
- Last updated
- 6 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment
- ClinicalTrials.gov ID
- NCT07511829
- Acronym / sponsor ID
- WATCH Tranfuse / 18950
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- University of OxfordUniversity, hospital or other
- Study start
- 17 Feb 2026 (actual)
- Primary completion
- 1 Apr 2027 (estimated)
- Study completion
- 1 Sep 2027 (estimated)
- First posted
- 6 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cancer treatments such as chemotherapy often affect healthy cells as well as the cancer cells and this can lead to side-effects such as low blood counts - anaemia. This can cause severe fatigue, shortness of breath and brain fog and may need regular blood transfusions. Their quality of life (QoL) is often very poor during treatment because of these side effects, and it is hard to deal with.
Doctors use blood tests to decide whether a patient is well enough for treatment and when to start treatment. However, blood tests do not tell us how a person feels, and it is not the same in everyone. We need a better way for doctors to monitor patients' QoL and these symptoms so that they are physically and emotionally able to continue their treatment. It is hard for doctors to accurately assess this through speaking to their patients and doctors do not record or discuss these effects of treatment very well with patients.
The aim of this study is to better understand how people feel during their treatment and how we can best use blood transfusions to maintain QoL.
80 adult patients who are starting blood cancer treatments will be asked to answer questionnaires about how they are feeling and their symptoms during their treatment. Participants will be asked to wear a smartwatch to measure their physical activity levels. Activity data collected will then be compared with their reported QoL and blood counts to help us understand when patients can tolerate difficult treatments the best and how blood transfusions affect this.
Patients, their family and carers will be invited to take part in an interview to understand their views on how we can improve their care, QoL and access to transfusions.
A better understanding of the impact of low blood counts on QoL can help us use blood transfusions to benefit patients' lives. This work will better match transfusions to individual peoples' needs and therefore 'personalise' blood transfusion care.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Months
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| MDS | – | Device: Axvitiy Ax3 accelorometerParticipants with MDS |
| AML | – | Device: Axvitiy Ax3 accelorometerParticipants with AML |
| Myeloma | – | Device: Axvitiy Ax3 accelorometerParticipants with myeloma |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants will be patients who have been diagnosed with haematological malignancies (MDS, AML and myeloma)
Key inclusion criteria (6 listed)
- Patients aged ≥18 years with WHO-defined MDS or mixed myeloproliferative/myelodysplastic neoplasm overlap syndromes (MPN/MDS), myeloma and AML
- Intention to undertake disease modifying treatment
- Life expectancy ≥ 6 months
- Able to complete quality of life questionnaires
- Willing and able to provide informed consent for participation in the study
Key exclusion criteria (7 listed)
- Poor performance/functional status (Eastern Cooperative Oncology Group system ECOG ≥3)
- Participants with known arrhythmias or other significant cardiological conductivity disorders
- Patients with severe comorbidities
- Patients with known skin allergies or conditions that in the opinion of the investigator would compromise the safety of the patient or quality of the data
- Hospitalised patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Axvitiy Ax3 accelorometerParticipants will wear the accelometer for 2 months | Device | AML, MDS, Myeloma |
Primary outcome
Activity Monitoring
Time frame: 2 months
To collect QoL data and activity data during an observational study to understand QoL through 2 treatment cycles of treatment exploring correlations of QoL with both Haemoglobin (Hb) and activity data.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Apr 2026.
Related trials for MDS (Myelodysplastic Syndrome)
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Active, not recruitingPhase 1/2
Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
High Grade Myelodysplastic Syndromes
RecruitingPhase 1/2
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Not yet recruitingPhase 1
ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Matthew H Poynton, MBBS principal investigator
University of Oxford
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of MDS (Myelodysplastic Syndrome) and AML (Acute Myeloid Leukemia), run by University of Oxford at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Matthew H Poynton, MBBS (+447742990230, matthew.poynton@linacre.ox.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Activity Monitoring (time frame: 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2026.